The role of WT1 (Wilm's tumor suppressor gene) in breast cancer is controversial, with evidence for both tumorpromoting and tumor-suppressing activities. In order to address this question, we expressed different WT1 isoforms in the mammary epithelial cell line H16N-2, which does not express endogenous WT1. Cells were stably transfected with either WT1 (ÀEx5/ÀKTS) or WT1 ( þ Ex5/ þ KTS) under the control of the inducible metallothionein promoter. Induction of WT1 (ÀEx5/ ÀKTS) upregulated p21, causing a slowing of proliferation and a G2-phase cell cycle arrest. In artificial basement membrane, the WT1 (ÀEx5/ÀKTS) isoform promoted the appearance of highly organized acinar cellular aggregates. In contrast, WT1 ( þ Ex5/ þ KTS) had no effect on p21 or proliferation, but rather caused an epithelial-mesenchymal transition and a redistribution of E-cadherin from the cell membrane to the cytoplasm. This isoform also causes the cellular aggregates growing in artificial basement membrane to appear significantly less organized than control cells. Thus, different WT1 isoforms have distinct effects in this cell line, suggesting that depending on the ratio of WT1 isoform expression in mammary epithelial cells, WT1 could function to either promote or suppress a transformed phenotype.
Introduction
The WT1 (Wilm's tumor suppressor gene) gene encodes a zinc finger transcription factor that has been implicated in the pathogenesis of breast cancer. Silberstein et al. (1997) reported that WT1 is expressed in mammary epithelial cells, with higher levels of expression in myoepithelium than in luminal epithelium. They also reported a loss of WT1 expression in most breast tumors, and they observed a correlation between loss of WT1 expression and expression of the estrogen receptor (ER). They, therefore, concluded that WT1 plays a tumor suppressor role in breast cancer. Consistent with this was a report by Zhang et al. (2003) that WT1 suppresses the clonal growth of MDA-MB-231 cells in soft agar. In contrast, our group reported overexpression of WT1 in breast cancer (Loeb et al., 2001) . Using reverse transcription-polymerase chain reaction (RT-PCR), we were only able to detect WT1 expression in one of 20 samples of mammary epithelium, but we detected WT1 expression in 27 of 31 primary breast carcinoma specimens. Subsequently, Miyoshi et al. (2002) reported a correlation between increased WT1 expression and poor long-term survival in women with breast cancer, and Zapata- Benavides et al. (2002) reported a correlation between WT1 expression levels and the proliferative rates of breast cancer cell lines. Taken together, these data suggest that WT1 might function as a tumor-promoting gene in breast cancer.
Complex transcriptional and translational regulation of the WT1 gene results in the expression of several protein isoforms. The most abundant of these isoforms result from two independent alternative splicing events (Haber et al., 1991) . One of these alternative splices includes or excludes exon 5 from the mature mRNA, resulting in proteins that contain or lack a 17 amino acid segment in the N-terminal transcriptional regulatory domain. The other alternative splice involves the use of one of the two distinct splice acceptor sites at the N-terminus of exon 10, resulting in the inclusion of three additional amino acids (KTS) in the larger protein isoform, altering the spacing of the zinc-fingers that compose the DNA-binding domain. The presence or absence of this so-called KTS insert has profound functional consequences for the mature protein, affecting both DNA-binding and subcellular localization, but the functional importance of exon 5 remains unclear (Larsson et al., 1995; Davies et al., 1998; Natoli et al., 2002; Reynolds et al., 2003) .
Variable expression of WT1 isoforms in breast tumors has been reported (Silberstein et al., 1997; Loeb et al., 2001) . We, therefore, hypothesized that different WT1 isoforms might have different effects on mammary epithelial cells, thus accounting for the conflicting reports of the role of this gene in the development of breast cancer. To test this hypothesis, we expressed two distinct WT1 isoforms in the H16N-2 cell line. This immortalized, but not transformed, mammary epithelial cell line does not express endogenous WT1 (Loeb et al., 2001) . Because they are the most structurally divergent isoforms, we chose to investigate the role of the WT1 isoform containing both exon 5 and the KTS insert (designated WT1 ( þ Ex5/ þ KTS)) and the isoform lacking both these alternatively spliced sequences (designated WT1 (ÀEx5/ÀKTS)). We found that WT1 (ÀEx5/ÀKTS) inhibited proliferation and promoted an acinar growth pattern in cells surrounded by extracellular matrix, characteristics of a tumor suppressor gene, whereas WT1 ( þ Ex5/ þ KTS) caused a morphological transition from an epithelial to a more mesenchymal phenotype, accompanied by alterations in the expression of E-cadherin and vimentin, consistent with a tumor-promoting function. Gene expression profiling revealed that these WT1 isoforms induced distinct gene expression patterns consistent with the observed phenotypic differences. These data support the hypothesis that different WT1 isoforms have distinct effects on mammary epithelial cells.
Results

Establishment of stable transfectants
H16N-2 cells were transfected with one of four different plasmids, and stable transfectants were isolated by selection with G418. The plasmids designated pCB6WT(À/À) and pCB6WT( þ / þ ) direct the expression of WT1 isoforms ((ÀEx5/ÀKTS) and ( þ Ex5/ þ KTS), respectively) under the control of the constitutively active cytomegalovirus (CMV) immediate-early promoter. Plasmids designated pMTWT(À/À) and pMTWT( þ / þ ) direct the expression of the same WT1 isoforms under the control of the zinc-inducible metallothionein promoter. Although cell lines expressing WT1 (ÀEx5/ÀKTS) under the control of the metallothionein promoter were readily obtained, only one stably transfected clone that constitutively expressed this isoform was obtained, despite numerous attempts. In contrast, WT1 ( þ Ex5/ þ KTS) was easily expressed both constitutively and in an inducible form. Cell lines with inducible expression of WT1 (ÀEx5/ÀKTS) were designated H16NMTWTA1, A2, and A3 and cell lines with inducible expression of WT1 ( þ Ex5/ þ KTS) were designated H16NMTWTD1, D2 and D3. Control cell lines were designated H16NMT1, H16NMT2 and H16NMT3. Western blotting was performed to verify expression of transfected WT1 proteins (Figure 1 ). Because there was only one clone constitutively expressing WT1 (ÀEx5/ÀKTS), further work was limited to the inducible expression system. Data obtained with H16NMTWTA1 and H16NMTWTD1 cells are shown, but all results were confirmed in multiple subclones.
Effect of WT1 isoforms on proliferation
We hypothesized that it was difficult to obtain cell lines that constitutively express WT1 (ÀEx5/ÀKTS) because this isoform interferes with proliferation. To test this hypothesis, we performed proliferation assays using cell lines stably transfected with the WT1 isoforms under the control of the metallothionein promoter. Cells were plated with or without ZnCl 2 to induce WT1 expression, and relative cell number was determined after 48 h. Induction of WT1 (ÀEx5/ÀKTS) resulted in a significant slowing of proliferation, induction of WT1 ( þ Ex5/ þ KTS) had no effect, and the addition of ZnCl 2 to control cells did not affect their proliferation (Figure 2a ). Cell cycle analysis revealed that WT1 (ÀEx5/ÀKTS) causes an accumulation of cells in the G2 phase of the cell cycle, but the addition of ZnCl 2 to the other cell lines had no effect on cell cycle distribution (Figure 2b ). Thus, WT1 (ÀEx5/ÀKTS) slows the proliferation of H16N-2 cells through induction of a G2-cell cycle arrest, whereas WT1 ( þ Ex5/ þ KTS) does not affect proliferation.
WT1 (ÀEx5/ÀKTS) upregulates p21 expression in Saos2 cells (Englert et al., 1997) , but not in 32D cl3 cells (Loeb et al., 2002) . Because p21 causes a cell cycle arrest and is a WT1 target gene in some cell lines, we investigated whether upregulation of p21 accompanied the WT1 (ÀEx5/ÀKTS)-induced cell cycle arrest in H16N-2 cells. As determined by western blotting, induction of WT1 (ÀEx5/ÀKTS), but not WT1 ( þ Ex5/ þ KTS), upregulated p21 expression (Figure 2c ). These data strongly suggest that WT1 (ÀEx5/ÀKTS) induces a G2-phase cell cycle arrest through upregulation of p21.
Effect of WT1 isoforms on morphology
It was difficult to generate clones constitutively expressing WT1 (ÀEx5/ÀKTS), and we also noticed that the cells expressing WT1 ( þ Ex5/ þ KTS) had a different morphology from control cells and from cells expressing WT1 (ÀEx5/ÀKTS). Control cells grow with an epithelial morphology, tending to cluster together and form a regular, cobblestone pattern ( Figure 3a) . Cells stably transfected with inducible WT1 (ÀEx5/ÀKTS) grow in a similar pattern (Figure 3b ). In contrast, cells transfected with WT1 ( þ Ex5/ þ KTS) tend to grow as individual cells, rather than in clusters, and tend to have a more spindle-like morphology ( Figure 3c ). The addition of ZnCl 2 to cultures of the transfected cells did not alter their morphology, but this probably reflects Effects of WT1 isoforms on breast epithelial cells EA Burwell et al leaky WT1 expression from the metallothionein promoter. It is unlikely that this morphologic distinction is a coincidence, unrelated to WT1 expression, because the morphology was noted in all six clones expressing inducible WT1 ( þ Ex5/ þ KTS) and in none of the other cell lines. This suggests that expression of the WT1 ( þ Ex5/ þ KTS) isoform might participate in an epithelial-mesenchymal transition. In addition to tissue culture plastic, we also evaluated the morphology of transfected cells in Matrigel, a solubilized basement membrane preparation that more closely mimics in vivo growth conditions. We observed two distinct populations of cells: one that settled to the bottom and grew on plastic surrounded by the dense extracellular matrix, and the others that grew suspended within the matrix. After 4-5 days in culture, there were distinct morphological differences among the cell lines. The control cells that settled to the bottom grew in loose, disorganized clusters ( Figure 4a ). Cells expressing WT1 ( þ Ex5/ þ KTS), in contrast, grew with a spindlelike morphology reminiscent of the morphology of these cells growing on plastic (Figure 4b ). The cells expressing WT1 (ÀEx5/ÀKTS) grew in more tightly adherent clusters, with a flatter, more epithelial morphology (Figure 4c) . Thus, cells growing on a flat surface but Effects of WT1 isoforms on breast epithelial cells EA Burwell et al surrounded by extracellular matrix exhibited WT1 isoform-dependent morphologic differences just as the cells growing in standard tissue culture did.
The morphologic differences of the cells growing in suspension were quite similar. The control cells grew in loosely adherent clusters with little obvious organization (Figure 4d ). The WT1 ( þ Ex5/ þ KTS) transfectants grew in an even more disorganized manner, and many of the clusters had spindle-like cells growing out from them ( Figure 4e ). In contrast, the cells transfected with WT1 (ÀEx5/ÀKTS) grew in very tightly adherent clusters, with a highly organized cellular arrangement reminiscent of mammary acini (Figure 4f ). Clusters such as these were never observed in cultures of control cells or cultures of cells expressing WT1 ( þ Ex5/ þ KTS). Thus, the morphology of H16N-2 cells is profoundly affected by WT1 expression in an isoform-specific manner.
Molecular correlates of altered morphology
The morphologic changes that we observed suggest the possibility that WT1 ( þ Ex5/ þ KTS) can initiate an epithelial-mesenchymal transition in mammary epithelial cells. One of the hallmarks of an epithelial-mesenchymal transition is the redistribution of E-cadherin from the cell membrane to the cytoplasm. Immunocytochemistry was, therefore, performed to determine if WT1 affects the subcellular distribution of E-cadherin. Interestingly, whereas the subcellular distribution of b-catenin was unaffected by WT1 (data not shown), there was a marked alteration in the localization of E-cadherin in cells expressing WT1 ( þ Ex5/ þ KTS). In both control cells and cells expressing WT1 (ÀEx5/ÀKTS), E-cadherin is expressed almost exclusively at the cell surface (Figure 5a and b) . In contrast, in cells expressing WT1 ( þ Ex5/ þ KTS), immunofluorescence reveals a more diffuse expression pattern of E-cadherin, with much less distinct localization to the cell membrane (Figure 5c ). We also evaluated E-cadherin expression levels by Western blotting and found that WT1 (ÀEx5/ÀKTS) modestly upregulated expression, quantified by scanning densitometry as a 60% increase in protein level, whereas induction of WT1 ( þ Ex5/ þ KTS) had no effect (data not shown). (Figure 5d ). These observations are consistent with the morphologic changes we observed. Taken together, the increased expression of vimentin and redistribution of E-cadherin support the idea that WT1 ( þ Ex5/ þ KTS) induces a mesenchymal phenotype in these cells.
To further evaluate the effects of different WT1 isoforms, we performed gene expression profiling. We isolated RNA from cell lines expressing WT (ÀEx5/ ÀKTS) or WT1 ( þ Ex5/ þ KTS) before and after induction of WT1. Control cells, with or without ZnCl 2 , were used for comparison. Of the 440 genes evaluable, 36 (8.2%) were upregulated by both WT1 isoforms, 14 (3.2%) were upregulated by WT1 ( þ Ex5/ þ KTS) but not WT1 (ÀEx5/ÀKTS), and one was upregulated by WT1 (ÀEx5/ÀKTS) but not WT1 ( þ Ex5/ þ KTS). In addition, seven (1.6%) were downregulated by both isoforms, whereas two were downregulated by either one isoform or the other. Genes were defined as upregulated or downregulated if their expression was altered by at least 2.5-fold upon addition of ZnCl 2 to cultures of both cell lines expressing the indicated WT1 isoform under the control of the metallothionein promoter. In addition, the gene expression profile of the cells constitutively expressing WT1 (ÀEx5/ÀKTS) matched the profile of cells in which expression of this isoform had been induced by ZnCl 2 (data not shown). Genes whose expression was altered in only one cell line expressing a particular isoform, or whose expression was altered by the addition of ZnCl 2 to cultures of the control cell lines, were not considered to be affected by WT1. Representative genes are reported in the Supplementary Information, and a full description of gene expression profiling of WT1 isoforms in these cells will be published separately. We used RT-PCR to independently confirm the altered regulation of a number of the genes identified in these experiments. For example, using semiquantitative RT-PCR, we were able to confirm upregulation of B-raf by both isoforms of WT1 (Figure 6a) , and using quantitative RT-PCR we confirmed that WT1 ( þ Ex5/ þ KTS), but not WT1 (ÀEx5/ÀKTS), upregulates ribosomal protein S6 kinase expression more than the 2.5-fold threshold (Figure 6b ).
The largest subset of genes regulated by WT1 is those regulated by both isoforms. Twenty-four of these 36 genes (67%) have been firmly implicated in either normal mammary gland biology, mammary carcinogenesis, or both the processes. Interestingly, the one gene upregulated by WT1 (ÀEx5/ÀKTS) and not by WT1 ( þ Ex5/ þ KTS), albumin, is a gene associated with mammary glad differentiation -albumin being a major protein found in colostrum (Velona et al., 1999) . One of the two genes downregulated by this isoform alone, Figure 5 WT1 affects localization of E-cadherin and expression of vimentin. H16NMT1 (a), H16NMTWTA1 (b) and H16NMTWTD1 (c) cells were grown on glass slides in the presence of 75 mM ZnCl 2 . Immunocytochemistry was performed with an antibody against E-cadherin. There was no staining with an isotype control (data not shown). In the cells expressing WT1 (ÀEx5/ ÀKTS), there is increased staining that is localized to the periphery of the cells. In the cells expressing WT1 ( þ Ex5/ þ KTS) there is decreased staining and the most intense staining is cytoplasmic. For the experiment in (d), H16NMT1 (control), H16NMTWTD1 ( þ Ex5/ þ KTS) and H16NMTWTA1 (ÀEx5/ÀKTS) cells were treated overnight with ( þ ) or without (À) 50mM ZnCl 2 . Cell lysates were subjected to Western blotting with antibody against vimentin. Equal protein loading was confirmed by Western blotting with antibody against tubulin. (a) RNA was isolated from the indicated cell lines treated with ( þ ) or without (À) 50 mM ZnCl 2 and reverse transcribed. The cDNA was used for PCR using primers specific for B-raf. After 30 cycles, PCR products were evaluated by agarose gel electrophoresis. Equal loading of cDNA in each reaction was confirmed by performing PCR using primers specific for the ribosomal RNA 36B4. (b) The same cDNA was used for quantitative RT-PCR using primers specific for ribosomal protein S6 kinase. Reactions were normalized by co-amplification of the housekeeping gene GAPDH. The dashed line indicates the 2.5-fold amplification that was used to define gene induction as discussed in the text.
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HIV-1 Rev binding protein, has not been previously associated with breast cancer, but the other, transforming growth factor-a, is thought to be an autocrine growth factor for breast cancer, acting by binding to and activating epidermal growth factor receptors (Lo et al., 2005) . Thus, the gene expression changes induced by WT1 (ÀEx5/ÀKTS) are consistent with its phenotypic effects opposing mammary carcinogenesis. In contrast, among the genes upregulated by WT1 ( þ Ex5/ þ KTS) but not by WT1 (ÀEx5/ÀKTS) are genes encoding hyaluronoglucosaminidase (Udabage et al., 2005) , ribosomal protein S6 kinase (Barlund et al., 2000) , vascular endothelial growth factor (Kolch et al., 1995) and erbB3 (Lemoine et al., 1992) that have been implicated in the pathogenesis of breast cancer. Thus, the gene expression changes we detected upon induction of individual WT1 isoforms reflect the phenotypic differences seen in cells expressing these isoforms.
Discussion
There are conflicting data in the literature regarding the role of WT1 in mammary carcinogenesis. Silberstein et al. (1997) reported loss of WT1 expression in breast tumors, and Zhang et al. (2003) reported observations consistent with a tumor suppressor role. In contrast, our group reported overexpression of WT1 in breast tumors as compared with normal mammary epithelium (Loeb et al., 2001) , and Zapata- Benavides et al. (2002) reported data consistent with an oncogenic role. To directly address these conflicting data, we expressed different WT1 isoforms in a mammary epithelial cell line that lacks endogenous WT1 expression. Our findings confirm our hypothesis that WT1 isoforms have distinct functions in mammary epithelial cells. WT1 (ÀEx5/ ÀKTS) slows proliferation, causes a cell cycle arrest in G2, upregulates p21 and causes the cells to grow in an organized, acinar morphology in three-dimensional culture. In contrast, WT1 ( þ Ex5/ þ KTS) causes the cells to assume a mesenchymal morphology, causes disorganized aggregation when grown with artificial basement membrane, and causes increased vimentin expression and a redistribution of E-cadherin from the cell membrane into the cytoplasm, all characteristics expected of an oncogene. Gene expression profiles of H16N-2 cells expressing different WT1 isoforms were consistent with biochemical and morphologic findings -WT1 ( þ Ex5/ þ KTS) differentially upregulated genes like ribosomal S6 kinase that are associated with malignant transformation. Taken together, these data strongly suggest that different WT1 isoforms have profoundly different effects on mammary epithelial cell biology.
The mechanism by which WT1 (ÀEx5/ÀKTS) slows proliferation and upregulates differentiation-associated genes is most likely related to its role as a transcription factor. Both p21 and E-cadherin have previously been shown to be WT1 target genes, and effects on these targets in H16N-2 cells could account for the cell cycle arrest and morphologic effects that we reported. The most striking effect of WT1 ( þ Ex5/ þ KTS) in H16N-2 cells is on their morphology, which can be at least partially explained by a redistribution of E-cadherin in the WT1-expressing cells. WT1 might directly affect the expression of a gene whose product is critical for proper localization of E-cadherin in adherens junctions. Alternatively, WT1 ( þ Ex5/ þ KTS) could affect which E-cadherin splice forms are expressed. This isoform of WT1 has been implicated in regulation of alternative splicing (Davies et al., 1998) , and perhaps this activity is responsible for the observed effect on E-cadherin localization. This would be consistent with a lack of effect of WT1 (ÀEx5/ÀKTS), which has not been implicated in the regulation of mRNA splicing. In addition to differential effects on transcription and RNA splicing, differential interactions with heterologous proteins might also contribute to the distinct phenotypic effects we observed. WT1 has been shown to physically interact with a number of other proteins, including estrogen receptor-a (Reizner et al., 2005) , a transcriptional regulator with a profound impact on mammary epithelial cell biology, p53 (Maheswaran et al., 1993) , a critical gene in the development of breast cancer, and others (Loeb, 2006) . Future work will investigate whether WT1 isoforms differ in these protein/protein interactions.
We observed both qualitative and quantitative differences in function between the WT1 isoforms, and the combined effect of these differences probably underlies the distinct phenotypic changes they cause. The differential regulation of p21 protein expression is an example of a qualitative difference, and the effect on RPS6K expression is a quantitative difference. Focusing on these two genes, WT1 (ÀEx5/ÀKTS) causes a significant increase in p21 expression and only a modest increase in RPS6K expression, and the combined effect is a slowing of cell cycle progression. In contrast, WT1 ( þ Ex5/ þ KTS) does not affect p21 expression but significantly upregulates RPS6K, accounting for the lack of cell cycle arrest in cells expressing only this isoform.
How can these seemingly contradictory functions of WT1 be integrated into a single model of WT1 function in mammary carcinoma? We investigated the function of individual WT1 isoforms expressed in isolation, but primary breast tumors frequently express multiple isoforms (Silberstein et al., 1997; Loeb et al., 2001) . Thus, the net effect of WT1 will probably reflect a balance of the effects of different isoforms. In the breast tumors our group studied, some tumors that expressed only isoforms containing exon 5 and the KTS insert were found, and the remainder of the tumors expressed both splice variants, but with a predominance of isoforms containing these regions. Thus in all of the tumors, the major WT1 isoform, and the form that would be expected to dictate the phenotype of the cells, was WT1 ( þ Ex5/ þ KTS) -the isoform with oncogenic characteristics.
Our results echo findings reported by Hewitt and Saunders (1996) , who noted that transfection of cells with WT1 isoforms lacking exon 5 slowed their proliferation, whereas isoforms containing exon 5 altered cellular morphology. Our results extend these findings to a different lineage (mammary epithelial cells), and begin to address the mechanism by which WT1 affects proliferation and morphology. The specific role and importance of exon 5 in the function of WT1 is a matter of some debate. Natoli et al. (2002) demonstrated that mice engineered to only express WT1 isoforms lacking exon 5 develop normally and lactate normally. Our findings do not directly address the relevance of exon 5 for mammary carcinogenesis, because the isoforms we investigated differ at both alternatively spliced sites. However, our results are consistent with those of Natoli et al. (2002) -our data support a role of WT1 (ÀEx5/ÀKTS) in normal mammary development, including expression of albumin, and suggest a role for WT1 ( þ Ex5/ þ KTS) in neoplastic transformation, but not normal breast development. Our findings are also in line with data regarding the role of WT1 in hematopoiesis, with reports that WT1 ( þ Ex5/ þ KTS) interferes with hematopoietic differentiation (Inoue et al., 1998) , whereas WT1 (ÀEx5/ÀKTS) potentiates this pathway (Loeb et al., 2003) .
In summary, we found that in H16N-2 mammary epithelial cells, WT1 isoforms had distinct effects. WT1 (ÀEx5/ÀKTS) has some characteristics of a tumor suppressor gene: slowing proliferation and inducing a cell cycle arrest. In contrast, WT1 ( þ Ex5/ þ KTS) has some characteristics of an oncogene: causing an epithelial-mesenchymal transition and decreasing the cell membrane expression of E-cadherin. This difference in function of WT1 isoforms is consistent with the isoform expression pattern we observed in clinical samples (Loeb et al., 2001) . The concordance between our observations in primary breast tumors and the functional differences seen in cell culture strengthens our contention that WT1 ( þ Ex5/ þ KTS) contributes to neoplastic transformation of mammary epithelial cells.
Materials and methods
Complete details given in Supplementary materials.
Cell culture, plasmids and transfection H16N-2 mammary epithelial cells were grown in mammary epithelial growth medium (MEGM) supplemented with 10% fetal bovine serum. Cells were transfected with plasmids that contain the cDNA for WT1 (ÀEx5/ÀKTS) or WT1 ( þ Ex5/ þ KTS) under the control of the CMV immediate-early promoter or under the control of the sheep metallothionein promoter as described (Loeb, 2003 (Loeb, , no. 1197 .
Immunofluorescence microscopy Cells were incubated overnight with 75 mM ZnCl 2 , rinsed, fixed and permeablized. After incubation with primary antibodies recognizing b-catenin or E-cadherin (both from BD Pharmingen, San Diego, CA, USA; catalog numbers 610153 and 610181), cells were rinsed and incubated with fluoresceinconjugated goat-anti-mouse secondary antibodies (Molecular Probes Inc., Eugene, OR, USA).
Western blotting
Total cellular protein was run on 4-12% bis-tris gels using MOPS buffer, blotted onto polyvinylidine difluoride (PVDF) membranes, and blocked overnight. Primary antibodies were diluted into blocking solution as follows: WT1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, SC-192) 1:1000; p21 (BD Pharmingen, 556430) 1:500; tubulin (Sigma-Aldrich, St Louis, MO, USA, T9026) 1:10 000; Vimentin (Santa Cruz Biotechnology, SC 5565) 1:200.
Proliferation, cell cycle analysis and morphology MTT assays. MTT proliferation assays were performed according to manufacturer's instructions (Chemicon, Temecula, CA, USA).
Cell cycle analysis. Cells were harvested in 'Magic Solution' (0.6% NP-40, 3.7% formaldehyde, 11 mg/ml Hoechst 33258 (Molecular Probes) in PBS), and absorbance quantified using a FACScalibur (Becton Dickinson, Franklin Lakes, NJ, USA) and CellQuest Pro software (Becton Dickinson).
Gene expression profiling cDNA was used to probe an array (OHS-802, SuperArray Bioscience Corporation, Frederick, MD, USA) containing 440 cancer-related genes. Reverse transcription, array hybridization, and data production were performed by SuperArray.
Polymerase chain reaction Semiquantitative RT-PCR. The sequences of the primers used to detect B-raf cDNA were as follows: 5 0 -GAAGACCT CACAGTAAAAATAGGTGA-3 0 and 5 0 -CCACAAAATG GATCCAGACA-3 0 . Other PCR sequences are as published.
Quantitative RT-PCR. Primers specific to RPS6K and to the housekeeping gene GAPDH were obtained from SuperArray Bioscience (Fredrick, MD, USA). Amplification was performed in 40 cycles of 951C for 15 s and 601C for 1 minute.
